Display options
Cite
Pang HB, Braun GB, Ruoslahti E. Neuropilin-1 and heparan sulfate proteoglycans cooperate in cellular uptake of nanoparticles functionalized by cationic cell-penetrating peptides. Sci Adv. 2015;1(10):e1500821doi: 10.1126/sciadv.1500821.
Pang, H. B., Braun, G. B., & Ruoslahti, E. (2015). Neuropilin-1 and heparan sulfate proteoglycans cooperate in cellular uptake of nanoparticles functionalized by cationic cell-penetrating peptides. Science advances, 1(10), e1500821. https://doi.org/10.1126/sciadv.1500821
Pang, Hong-Bo, et al. "Neuropilin-1 and heparan sulfate proteoglycans cooperate in cellular uptake of nanoparticles functionalized by cationic cell-penetrating peptides." Science advances vol. 1,10 (2015): e1500821. doi: https://doi.org/10.1126/sciadv.1500821
Pang HB, Braun GB, Ruoslahti E. Neuropilin-1 and heparan sulfate proteoglycans cooperate in cellular uptake of nanoparticles functionalized by cationic cell-penetrating peptides. Sci Adv. 2015 Nov 06;1(10):e1500821. doi: 10.1126/sciadv.1500821. eCollection 2015 Nov. PMID: 26601141; PMCID: PMC4640594.
Copy Download .nbib Format: NLM
Share it on

Sci Adv. 2015 Nov 06;1(10):e1500821. doi: 10.1126/sciadv.1500821. eCollection 2015 Nov.

Neuropilin-1 and heparan sulfate proteoglycans cooperate in cellular uptake of nanoparticles functionalized by cationic cell-penetrating peptides.

Science advances

Hong-Bo Pang, Gary B Braun, Erkki Ruoslahti

Affiliations

  1. Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA.
  2. Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA. ; Center for Nanomedicine and Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106-9610, USA.

PMID: 26601141 PMCID: PMC4640594 DOI: 10.1126/sciadv.1500821

Abstract

Cell-penetrating peptides (CPPs) have been widely used to deliver nanomaterials and other types of macromolecules into mammalian cells for therapeutic and diagnostic use. Cationic CPPs that bind to heparan sulfate (HS) proteoglycans on the cell surface induce potent endocytosis; however, the role of other surface receptors in this process is unclear. We describe the convergence of an HS-dependent pathway with the C-end rule (CendR) mechanism that enables peptide ligation with neuropilin-1 (NRP1), a cell surface receptor known to be involved in angiogenesis and vascular permeability. NRP1 binds peptides carrying a positive residue at the carboxyl terminus, a feature that is compatible with cationic CPPs, either intact or after proteolytic processing. We used CPP and CendR peptides, as well as HS- and NRP1-binding motifs from semaphorins, to explore the commonalities and differences of the HS and NRP1 pathways. We show that the CendR-NRP1 interaction determines the ability of CPPs to induce vascular permeability. We also show at the ultrastructural level, using a novel cell entry synchronization method, that both the HS and NRP1 pathways can initiate a macropinocytosis-like process and visualize these CPP-cargo complexes going through various endosomal compartments. Our results provide new insights into how CPPs exploit multiple surface receptor pathways for intracellular delivery.

Keywords: CendR pathway; cell-penetrating peptide; intracellular delivery; neuropilin-1; synchronized ultrastructural imaging; vascular permeability

References

  1. EMBO J. 2006 Jul 12;25(13):3045-55 - PubMed
  2. J Cell Biol. 1995 Jun;129(5):1229-40 - PubMed
  3. Br J Pharmacol. 2009 May;157(2):195-206 - PubMed
  4. J Control Release. 2005 Jan 20;102(1):247-53 - PubMed
  5. Science. 2010 May 21;328(5981):1031-5 - PubMed
  6. Nature. 2010 Apr 15;464(7291):1048-51 - PubMed
  7. Blood. 2008 Mar 1;111(5):2674-80 - PubMed
  8. Nat Commun. 2014 Oct 03;5:4904 - PubMed
  9. Nat Mater. 2014 Sep;13(9):904-11 - PubMed
  10. Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62 - PubMed
  11. J Biophys. 2011;2011:414729 - PubMed
  12. Mol Cancer Ther. 2006 May;5(5):1099-107 - PubMed
  13. Mol Ther. 2012 May;20(5):984-93 - PubMed
  14. Trends Mol Med. 2007 Oct;13(10):443-8 - PubMed
  15. J Biol Chem. 2001 Feb 2;276(5):3254-61 - PubMed
  16. Mol Cancer Ther. 2015 Jan;14 (1):120-8 - PubMed
  17. J Biol Chem. 2003 Sep 12;278(37):35109-14 - PubMed
  18. J Biol Chem. 1997 Jun 20;272(25):16010-7 - PubMed
  19. Mol Ther. 2003 Jul;8(1):143-50 - PubMed
  20. Cancer Cell. 2009 Dec 8;16(6):510-20 - PubMed
  21. J Mol Biol. 2013 Nov 15;425(22):4405-14 - PubMed
  22. J Am Chem Soc. 2007 Nov 28;129(47):14759-66 - PubMed
  23. J Control Release. 2015 Mar 10;201:14-21 - PubMed
  24. J Biol Chem. 2015 Jun 26;290(26):16451-62 - PubMed
  25. Cell. 1997 Aug 22;90(4):739-51 - PubMed
  26. Circ Res. 2008 Sep 12;103(6):e71-9 - PubMed
  27. Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6152-7 - PubMed
  28. J Immunol. 2001 Jan 15;166(2):1380-8 - PubMed
  29. Adv Drug Deliv Rev. 2014 Feb;66:2-25 - PubMed
  30. Front Oncol. 2013 Aug 27;3:216 - PubMed
  31. J Struct Biol. 2013 May;182(2):78-86 - PubMed
  32. Annu Rev Chem Biomol Eng. 2011;2:281-98 - PubMed

Publication Types

Grant support